...decortication, lung-sparing surgery, UCLA mesothelioma, P/D surgery, MARS trial, mesothelioma surgery
.../ref> His advocacy for preserving the lung proved prescient: the 2011 MARS trial confirmed that EPP offered no survival benefit and potentially harmed patie
...
17 KB (2,260 words) - 05:04, 25 May 2026
...decortication, lung-sparing surgery, UCLA mesothelioma, P/D surgery, MARS trial, mesothelioma surgery
.../ref> His advocacy for preserving the lung proved prescient: the 2011 MARS trial confirmed that EPP offered no survival benefit and potentially harmed patie
...
22 KB (2,918 words) - 23:25, 14 May 2026
...nd decortication (P/D) for malignant pleural mesothelioma including MARS 2 trial results, HITHOC protocols, patient selection criteria, complication rates,
...thelioma, lung-sparing surgery, extended pleurectomy decortication, MARS 2 trial, HITHOC, mesothelioma surgery, EPP vs P/D, macroscopic complete resection,
...
46 KB (6,121 words) - 05:05, 25 May 2026
...ing pleurectomy/decortication, extrapleural pneumonectomy, CRS-HIPEC, MARS trial results, eligibility criteria, and recovery timelines.
...pneumonectomy, EPP, P/D, CRS-HIPEC, peritoneal mesothelioma surgery, MARS trial, mesothelioma surgical options, mesothelioma treatment
...
43 KB (5,547 words) - 16:22, 2 May 2026
...S 2026 consensus, JAMA 2023 volume-outcome data, CRS-HIPEC learning curve, MARS-2, and questions to ask a center.
...mesothelioma center, STS 2026 consensus, CRS-HIPEC learning curve, MARS-2 trial, mesothelioma surgeon volume, multidisciplinary tumor board mesothelioma
...
43 KB (5,451 words) - 15:56, 26 May 2026
...technique, survival data by subgroup, the Sugarbaker favorable triad, MARS trial results, complications, quality of life, multimodal protocols, recurrence p
...lioma, EPP surgery, EPP vs P/D, mesothelioma surgery, Sugarbaker EPP, MARS trial mesothelioma, trimodal therapy mesothelioma, EPP survival rates, EPP compli
...
49 KB (6,529 words) - 23:25, 14 May 2026
...and pembrolizumab plus chemotherapy. Five-year data from the CheckMate 743 trial, published in February 2026, confirmed that immunotherapy more than doubles
...trating a mean survival advantage of 7 months for P/D. However, the MARS 2 trial raised fundamental questions about the benefit of surgery at all, finding t
...
55 KB (6,941 words) - 05:05, 25 May 2026
..., and [[Dr_Paul_Baas|Dr. Paul Baas's]] [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref>[
| style="padding:10px;" | MARS trial published
...
20 KB (2,497 words) - 23:25, 14 May 2026
..., and [[Dr_Paul_Baas|Dr. Paul Baas]]'s [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref n
* '''Surgery evolved from radical to conservative''' — The 2011 MARS trial showed extrapleural pneumonectomy offered no survival benefit, validating D
...
38 KB (4,762 words) - 23:25, 14 May 2026
...nivolumab plus ipilimumab ([[Immunotherapy_for_Mesothelioma|CheckMate 743 trial]]) transformed the treatment landscape, with the combination achieving a me
...y alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. ''Lancet Respir Med.'' 2024;12(5):349–360. PMID: 38740044. DOI: 10.1016/s2
...
51 KB (6,599 words) - 14:18, 25 April 2026
...adding:15px;" | '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many
...tly today than during Dr. Sugarbaker's peak years. Following the 2011 MARS trial, many centers shifted toward lung-sparing pleurectomy with decortication (P
...
28 KB (3,564 words) - 23:25, 14 May 2026
...nt paradigm shift 2020-2026: CheckMate 743, pembrolizumab approval, MARS 2 trial, CAR-T therapy
* [[Pleural Mesothelioma]] — Immunotherapy, MARS 2 trial, CAR-T cell therapy, and TTFields
...
25 KB (2,946 words) - 12:40, 21 May 2026
...hensive treatment guide including CheckMate 743 immunotherapy data, MARS 2 trial findings, CAR-T therapy, and current survival statistics.''<ref name="mlcpl
* Clinical trial eligibility
...
28 KB (3,459 words) - 13:51, 23 May 2026
...oma — diagnostic yield, staging accuracy, therapeutic procedures, MesoVATS trial results, port-site metastasis evidence, complication rates, MARS2 controver
...pleuroscopy, mesothelioma staging, port-site metastasis, SMART trial, PIT trial, HITHOC, thoracoscopic surgery mesothelioma
...
60 KB (7,810 words) - 23:26, 14 May 2026
...ctDNA)''' — Johns Hopkins phase 2 perioperative immune checkpoint blockade trial (PMID 40921804) showed that undetectable ctDNA after neoadjuvant immunother
| '''MARS2 trial''' || Extended P/D + chemo vs. chemo alone in resectable MPM; median OS 19.
...
54 KB (6,833 words) - 18:35, 25 May 2026
...cialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel w
The MAPS trial demonstrated that adding bevacizumab 15 mg/kg every 3 weeks extends median
...
38 KB (4,508 words) - 14:24, 21 May 2026
...ths for chemotherapy only, with 3.6x more serious adverse events<ref name="mars-2" />
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''MARS 2 Surgery Outcomes'''
...
99 KB (12,540 words) - 13:45, 25 May 2026
...ize:1.2em; color:#e8f4f8;">of mesothelioma lawsuits settle before reaching trial verdict<ref>[https://dandell.com/mesothelioma-lawsuit/ Mesothelioma Lawsuit
| style="padding:12px;" | Judge/jury decision after trial
...
91 KB (11,224 words) - 23:25, 14 May 2026
...n combined with pemetrexed, established by the landmark Phase III EMPHACIS trial that demonstrated a median survival of 12.1 months with the combination ver
...l function and pain scales at both 1 and 6 months after surgery. The MARS2 trial (2024) found that surgery was associated with worse quality of life and hig
...
47 KB (6,255 words) - 01:24, 10 May 2026
* [[Trial Preference|Trial Preference]]
...othelioma makes expedited legal action essential. Many jurisdictions offer trial preference or expedited scheduling for terminally ill plaintiffs, and famil
...
218 KB (26,785 words) - 23:07, 14 May 2026
